Cream tested alongside light therapy for mild-to-moderate plaque psoriasis
Tests a cream added to light therapy in adults with plaque psoriasis.
Plain-language title generated from the registry record
Registry title: Ceramol PSOR Cream as an Adjuvant Treatment in Patients With Mild-to-Moderate Psoriasis Treated With Narrowband UVB Phototherapy (CERAMOL PSOR CREMA)
Key facts
- Where
- Madrid, SpainSee the 3 sites
Where in Spain
- Hospital Universitario 12 de OctubreMadrid, SpainNo longer taking part
- Hospital Universitario de la PrincesaMadrid, SpainNo longer taking part
- Hospital Universitario Puerta de Hierro - MajadahondaMadrid, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Unifarco SpA
- Trial code
- NCT07849101
- Record updated
- 30 September 2026
- Original description
This is a multicenter, prospective, randomized, open-label, controlled clinical investigation to evaluate whether Ceramol PSOR cream, used as an adjuvant treatment, is superior to a comparator emollient cream in patients with mild-to-moderate plaque psoriasis undergoing narrowband UVB phototherapy. Participants apply the assigned cream topically once daily throughout one standard phototherapy cycle (36 ± 3 UVB sessions). The study assesses clinical response (PASI, body surface area), subjective symptoms (pruritus and dryness/tightness VAS), quality of life (DLQI), treatment satisfaction, and adherence to both the investigational product and phototherapy.Read full original descriptionShow less
Multicenter, Prospective, Randomized, Open-Label, Controlled, Two-Arm, Parallel-Group, Superiority Clinical Investigation on the Use of Ceramol PSOR Cream in Patients With Mild-to-Moderate Plaque Psoriasis Treated With Narrowband UVB Phototherapy: CERAMOL PSOR CREMA Study
This is a multicenter, prospective, randomized, open-label, controlled clinical investigation to evaluate whether Ceramol PSOR cream, used as an adjuvant treatment, is superior to a comparator emollient cream in patients with mild-to-moderate plaque psoriasis undergoing narrowband UVB phototherapy. Participants apply the assigned cream topically once daily throughout one standard phototherapy cycle (36 ± 3 UVB sessions). The study assesses clinical response (PASI, body surface area), subjective symptoms (pruritus and dryness/tightness VAS), quality of life (DLQI), treatment satisfaction, and adherence to both the investigational product and phototherapy.
Inclusion: Age ≥ 18 years; Clinical diagnosis of mild or moderate plaque psoriasis; Body surface area (BSA) involvement of 3-10%, excluding palms and soles; Planned treatment with narrowband UVB phototherapy as part of routine clinical practice; Presence of at least one psoriasis-associated symptom (pruritus/burning, dryness/tightness) with a VAS score ≥ 3 at study entry; Ability to understand and sign the Informed Consent Form; Willingness to use only the study product as the daily body moisturizer during the phototherapy cycle.
Exclusion: Patients receiving systemic pharmacological treatment for psoriasis; Patients receiving topical pharmacological treatment for psoriasis, or who discontinued such treatment less than one (1) week before enrollment; Any active dermatological condition unrelated to psoriasis that could interfere with study results; Cognitive impairment preventing completion of the study questionnaires.